Ym, the key resistance is around $7.13 plus or minus a few pennies. Oh wait, you didn't ask me. -sv
SP, I like your #$%$ howbeit a bit naive. Keep up the great effort. -sv (Market sentiment)
Ok SP500, I will. You tossed the gap aside and that was a fatal flaw given the stock dipped below $5. Secondly, you seem to have no appreciation for how the Bollinger Band on the bullish run has nearly been a predictor of recent. Thirdly, in your videos you guess a lot, and have been wrong multiple times because you have not contemplated market sentiment. Thanks for the opportunity. -sv
Ok, here ya go...
MACK - smart partnership, impressive phase 2 - could be a break-out stock triple percent return... hmmm
NPSP - will retrace below $20... at this point stay away from...
EXTR - can't comment outside my sector
SP500, Were you born head or feet first? You just won the IDI@T Thanksgiving Award in light of Arena plunging to the upper fours and filling a gap. But congratulations on being able to draw color lines. -stockvadar
SP500, Until you get past your pride about drawing lines any monkey can draw and start using tried and tested analytical tools, you're a bush-league comic. -stockvadar (Gee, I bet I just offended you because someone will say I wasn't being nice. Nice? This is about making money. GALE will retrace. QCOR will go up in 2014. And Arena will soar to new heights. But I'm dumb, mental, and stupid.)
The run is always before PDUFA. Play however you want to risk but better with house money. GALE is going to retrace for a while, so time your investment very carefully. -sv
Chasin, I have no problem with being honest. GALE is retracing so the strategy there is to wait for a retrace to buy back in, or to sell to register gains.
And Chasin, for you chagrin, I do place a buy on Questcor on its retrace at this point. I give you one more: ANIP should be shorted. -sv
I am familiar with Gale. I can see others like yourself are asking valid questions. Ok, I'll restudy, but for now I would put a BUY on Questcor and of course a STRONG BUY on Arena. -stockvadar
Ok Chasin, a little outside my thirst for low-ball biotechs, on the upside I do like Questcor going into 2014. IMO only. -stockvadar (Like I wrote, if I see other(s) I'll tell you.)
Leroy, In one respect I can appreciate your post. Especially anyone who put Belviq down the pipe. Well done. Nothing like risking your health to gauge an investment (Some will think I'm joking, I'm not!)
Reality here is that Arena is on a course for double digits. You as a trader understand that and I applaud you for trading on your knowledge obtained through trial and error. Right now I see Arena ultimately making a heavy run to the $12 - 16 range. -stockvadar
Paten, I do like Questcor, especially on the retrace of recent. I also understand the prevailing differences correctly highlighted by you. I have no argument with your erudite reply. However, in the case of Arena, I see a Sarepta-type Market sentiment at play, plus, and I'm not joking, I see Belviq piggy backing on Phen- and that's why I posted that. Phen- is a mega script and that's why Arena directed Eisai (you got it) to conduct a phase 4 to put Belviq on the back of Phen-. I also think Belviq will be tested with Metaformin (sp) and smoking cessation explored--though I'm less bullish on that one no thanks to Tiger. My angle is that while the things you note are true, and I am a big fan of Questcor, Arena has serious room to run to the upside. I wish you the best. -sv
Mist, you'll think I'm busting your chops, but a lot of people FOLLOW ME. -stockvadar
- I am openly calling Arena 'the' bullish winner going into year-end. People like Wetsu understand. Anyway, I wish you the very best!
Actually Gary, I don't. My record on biotech picking is only 80%, and my style creates a lot of riffs because even your reply implies emotion towards me. Myself, I read everything: positive or negative. Bullish or bearish. I pursue truth. In the case of Arena, I turned to those closest to me and told them, 'Buy Arena right now because it's going to make you a hefty gain.' But I don't publish that stuff anymore because why should I? I happen to think Arena will break into double digits and my thinking is based in hours of DD reading both sides of the same coin. I'll end with one example: Jack Leif is an unimpressive speaker but that dude carries a big stick unlike a good many other biotech CEOs that come across as used-car salesman. Jack gets abused all the time, but everyone knows, that boring CEO is one heck of a deal-maker. -sv
SP500, I figure you probably hate my guts (haha), but I do appreciate your attempt to read charts and I was deeply moved by your son's birth story. Thing is, you're stubborn and set in your ways not wanting someone to tell you (especially an insane poster) you need to pay more attention to MACD, RSI, and especially Bollinger Bands. I wish you the best, honestly. -sv
Paten, Questcor was/is a gem because Achthar gel was transferable into a number of different indications. Like Arena, it too was once a single digit stock. But Arena is like Questcor in that Belviq is going to target more than one indication, and/or do so by being combined with other FDA approved drugs. Plus, and someday I'll explain, Arena is running hot on APD811, and even more enticing, it's immuno-drug just getting thru phase 1. Arena is a Questcor and back in the day, the negative language about Questcor is/was exactly as it is now on Arena. -sv (BTW, I did correctly call Acadia much to the shagrin of AF and a host of others.)